IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 11, 2016, Pages 3195-3201

  Londoño, Maria Carlota ^a   Manzardo, Christian ^a   Rimola, Antoni ^a   Ruiz, Pablo ^a   Costa, Josep ^a   Forner, Alejandro ^a   Ambrosioni, Juan ^a   Agüero, Fernando ^a   Laguno, Montserrat ^a   Lligoña, Anna ^b   Moreno, Asunción ^a   Miró, Jose Maria ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; INTEGRASE INHIBITOR; INTERFERON; LEDIPASVIR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ANEMIA; ARTICLE; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; COMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG TOLERANCE; FATIGUE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MIXED INFECTION; RECURRENT DISEASE; TREATMENT RESPONSE; COINFECTION; COMPLICATION; GRAFT RECIPIENT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; COINFECTION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RIBAVIRIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84994537690     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw270     Document Type: Article

References (40)

1. Duclos-Vallee JC, Feray C, Sebagh M et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-17.
2. Miro JM, Montejo M, Castells L et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant 2012; 12: 1866-76.
3. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18: 716-26.
4. Antonini TM, Furlan V, Teicher E et al. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus coinfected patients to treat recurrence of hepatitis C virus infection after liver transplantation. AIDS 2015; 29: 53-8.
5. Crespo G, Marino Z, NavasaM, et al. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373-83 e1.
6. Castells L, Rimola A, Manzardo C et al. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. J Hepatol 2015; 62: 92-100.
7. Terrault N, Reddy KR, Poordad F et al. Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients. Am J Transplant 2014; 14: 1129-35.
8. Miro JM, Stock P, Teicher E et al. Outcome and management of HCV/HIV coinfection pre-and post-liver transplantation. A 2015 update. J Hepatol 2015; 62: 701-11.
9. Burton JR Jr, O'Leary JG, Verna EC et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014; 61: 508-14.
10. Coilly A, Roche B, Dumortier J et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2013; 60: 78-86.
11. Forns X, Samuel D, Mutimer D. Interim SVR12 results from the telaprevir phase 3B REPLACE study in treatment-naive stable liver transplant patients with genotype 1 HCV infection. J Hepatol 2014; 60: S481.
12. Carrion JA, Martinez-Bauer E, Crespo G et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-28.
13. Hezode C, Fontaine H, Dorival C et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-42 e4.
14. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-7 e1.
15. Curry MP, O'Leary JG, Bzowej N et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373: 2618-28.
16. Charlton M, Everson GT, Flamm SL et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649-59.
17. Poordad F, Schiff ER, Vierling JM et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016; 63: 1493-505.
18. Foster GR, Irving WL, Cheung MC et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 64: 1224-31.
19. Charlton M, Gane E, Manns MP et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-17.
20. Pungpapong S, Aqel B, Leise M et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1. after liver transplant. Hepatology 2015; 61: 1880-6.
21. Kwo PY, Mantry PS, Coakley E et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-82.
22. Brown RS Jr, O'Leary JG, Reddy KR et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real world experience from HCV-TARGET. Liver Transpl 2016; 22: 24-33.
23. Naggie S, Cooper C, Saag M et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 705-13.
24. Naggie S, Kim AY. PHOTON-2: hope for patients with HIV and HCV co-infection? Lancet 2015; 385: 1052-4.
25. Sulkowski M, Hezode C, Gerstoft J et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1. mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385: 1087-97.
26. Sulkowski MS, Naggie S, Lalezari J et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312: 353-61.
27. Wyles DL, Ruane PJ, Sulkowski MS et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 714-25.
28. Grant JL, Hawkins C, Brooks H et al. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection. AIDS 2016; 30: 93-8.
29. Campos-Varela I, Straley S, Agudelo EZ et al. Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients. Liver Transpl 2015; 21: 272-4.
30. Donato MF, Monico S, Malinverno F et al. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver Int 2014; 35: 1-4.
31. Belli L, Berenguer M, Rockenschaub SR et al. Impact of direct antiviral agents on inactivation/delisting of liver transplant candidates listed for decompensated C cirrhosis: a European study. J Hepatol 2016; 64: S153.
32. Pascasio J, Vinaixa C, Ferrer MT, et al. Interferon (INF)-free antiviral therapy in cirrhotic patients infected with hepatitis C on the waiting list for liver transplantation. Efficacy and impact on delisting and liver function. J Hepatol 2016; 64: S543.
33. Coilly A, Pageaux GP, Houssel-Debry P et al. Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAAs? Hepatology 2015; 62: 257A.
34. Llaneras J, Castells L, Santos B et al. Removal fromliver transplantation list of a hepatitis C virus-HIV coinfected patient after successful treatment with sofosbuvir and daclatasvir. Transpl Infect Dis 2016; doi:10.1111/tid.12538. [Epub ahead of print].
35. Chen T, Terrault NA. Perspectives on treating hepatitis C infection in the liver transplantation setting. Curr Opin Organ Transplant 2016; 21: 111-9.
36. Forns X, Charlton M, Denning J et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. Hepatology 2015; 61: 1485-94.
37. Afdhal N, Everson G, Calleja J et al. Effect of long-term viral suppression with sofosbuvir+ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. J Hepatol 2015; 62: S269.
38. European recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-236.
39. Gambato M, Lens S, Navasa M et al. Treatment options in patients with decompensated cirrhosis, pre-and post-transplantation. J Hepatol 2014; 61: S120-31.
40. German P, Garrison K, Pang P et al. Drug-drug interactions between anti-HCV regimen ledipasvir/sofosbuvir and antiretrovirals. In: Abstracts of the Twenty-second Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015. Abstract 82.